The agency has signaled broader interest in ensuring that companies operating in the health‑tech ecosystem maintain transparent data policies and do not engage in conduct that could disadvantage patients or healthcare providers.
The Federal Trade Commission says the settlement will increase transparency and competition across the entire drug supply chain.
Federal antitrust suit claims two pharmacy benefits managers worked together to suppress pharmacy reimbursements rates, fueling ongoing scrutiny of PBM practices.
The case against a US dental technology company suggests that regulators may be expanding scrutiny into medical device markets and digital health.
Key takeaways from the draft 2026 Merger Guidelines and practical advice.
This article examines the evolving federal and state AI enforcement landscape and outlines practical considerations for companies deploying AI technologies.
FTC argues that coordination between competitors in how they make employment decisions could violate federal law.
Jeffrey Oliver talked to GRIP about the surging pace of antitrust activity in 2026 and what we can expect from regulators in this space.
